BioXcel Therapeutics Inc
BTAI
Company Profile
Business description
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company’s commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Contact
555 Long Wharf Drive
New HavenCT06511
USAT: +1 475 238-6837
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
37
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,741.90 | 26.70 | -0.30% |
| CAC 40 | 7,804.87 | 14.60 | 0.19% |
| DAX 40 | 24,304.46 | 19.12 | -0.08% |
| Dow JONES (US) | 42,762.87 | 443.13 | 1.05% |
| FTSE 100 | 8,837.91 | 26.87 | 0.30% |
| HKSE | 23,792.54 | 114.43 | -0.48% |
| NASDAQ | 19,529.95 | 231.51 | 1.20% |
| Nikkei 225 | 37,741.61 | 187.12 | 0.50% |
| NZX 50 Index | 12,563.48 | 13.67 | -0.11% |
| S&P 500 | 6,000.36 | 61.06 | 1.03% |
| S&P/ASX 200 | 8,515.70 | 23.20 | -0.27% |
| SSE Composite Index | 3,385.36 | 1.26 | 0.04% |